Guardant Health to Ring Nasdaq Bell on August 28 for Shield™ Colorectal Cancer Test Launch
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology firm, will ring the Nasdaq opening bell at MarketSite in Times Square, New York on Wednesday, August 28, 2024. “Today, we…
Simulations Plus Restructures Business Units to Support Growth After Recent Acquisitions
Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation, simulation-enabled performance, intelligence solutions, and medical communications for the biopharma industry, has announced an optimization of its business unit and…
bluebird bio Receives Expected Nasdaq Notices
bluebird bio, Inc. (Nasdaq: BLUE) announced on August 20, 2024, that it received notices from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1). This is due…
BeMe Health Joins Hesperia Capital’s Portfolio with $12.5M in New Funding
BeMe Health, an innovator in digital behavioral health for teens, has secured over $12 million in new funding, marking a significant milestone ahead of its upcoming Series A round. This…
ADVI Health Acquires Partnership for Health Analytic Research
ADVI Health is excited to announce the acquisition of Partnership for Health Analytic Research (PHAR), a leading global consultancy specializing in health technology assessment (HTA) and health economics and outcomes…
SurGenTec’s B-MAN Bone Marrow Kit with Filtration Gains FDA Clearance
SurGenTec, a leader in orthopedic and spine technology, is excited to announce that its proprietary B-MAN Bone Marrow Aspirate Kit has received 510(k) clearance from the U.S. Food and Drug…
Techstars, Johns Hopkins, and CareFirst Launch Healthcare AI Accelerator in Baltimore
Techstars, Johns Hopkins University, and CareFirst BlueCross BlueShield (CareFirst) have announced a new collaboration to launch a healthcare accelerator program. This initiative aims to support early-stage entrepreneurs developing AI-driven solutions…
Invenra’s Antibody INV724 Gains FDA Rare Pediatric and Orphan Drug Designations for Neuroblastoma
Invenra Inc. is excited to announce that its innovative bispecific antibody, INV724, designed for the treatment of neuroblastoma, has received both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations…
VION Biosciences Acquires Echelon Biosciences, a Leader in Specialty Lipids and Nanoparticles
VION Biosciences, a life science platform company specializing in specialty reagents for research, diagnostics, and drug discovery, has announced the acquisition of Echelon Biosciences, a Salt Lake City-based supplier known…
FDA Clears AISAP’s CARDIO AI Ultrasound Diagnostic Software
AISAP, a medical technology company focused on AI-powered Point-of-Care Assisted Diagnosis (POCAD™) solutions, has received 510(k) clearance from the U.S. FDA for its innovative AISAP CARDIO software platform. This cloud-based,…
Pfizer-BioNTech’s Omicron KP.2 COVID Vaccine Approved by FDA
Pfizer Inc. and BioNTech SE announced that the U.S. FDA has approved their supplemental Biologics License Application for the Omicron KP.2-adapted COVID-19 vaccine (COMIRNATY®) for individuals aged 12 and older.…
EMulate Therapeutics demonstrates immune checkpoint knockdown in a glioblastoma mouse model
EMulate Therapeutics, Inc. has announced that the Open Journal of Biophysics (OJBIPHY) will publish its manuscript, titled “Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in…